Tomomi Toubai

List of Publications by Year
in descending order

33	1,971	393982 19	414034 32
papers	citations	h-index	g-index

34	34	34	3205
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Ivabradine as an Adjuvant Agent for Severe Heart Failure Occurring in the Early Phase after Allogeneic Hematopoietic Cell Transplantation. Internal Medicine, 2022, , .	0.3	3
2	How does transfusion-associated graft-versus-host disease compare to hematopoietic cell transplantation-associated graft-versus-host disease?. Transfusion and Apheresis Science, 2022, , 103405.	0.5	2
3	GPR109A in GVHD: friend or foe?. Blood, 2022, 139, 2271-2272.	0.6	0
4	Plasma Exchange as an Initial Treatment for Severe Bleeding Induced by Acquired Factor V Deficiency: A Case Report and Mini Literature Review. Acta Haematologica, 2021, 144, 82-87.	0.7	4
5	A unique three-way Philadelphia chromosome variant t(4;9;22)(q21;q34;q11.2) in a newly diagnosed patient with chronic phase chronic myeloid leukemia: a case report and review of theÂliterature. Journal of Medical Case Reports, 2021, 15, 285.	0.4	3
6	Recent Advances of Acute Kidney Injury in Hematopoietic Cell Transplantation. Frontiers in Immunology, 2021, 12, 779881.	2.2	11
7	Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease. Blood, 2020, 136, 429-440.	0.6	43
8	Host NLRP6 exacerbates graft-versus-host disease independent of gut microbial composition. Nature Microbiology, 2019, 4, 800-812.	5.9	36
9	Mitochondrial Deacetylase SIRT3 Plays an Important Role in Donor T Cell Responses after Experimental Allogeneic Hematopoietic Transplantation. Journal of Immunology, 2018, 201, 3443-3455.	0.4	22
10	Murine Models of Steroid Refractory Graft-versus-Host Disease. Scientific Reports, 2018, 8, 12475.	1.6	13
11	Microbial metabolite sensor GPR43 controls severity of experimental GVHD. Nature Communications, 2018, 9, 3674.	5.8	102
12	STAT3 Expression in Host Myeloid Cells Controls Graft-versus-Host Disease Severity. Biology of Blood and Marrow Transplantation, 2017, 23, 1622-1630.	2.0	7
13	IAPs protect host target tissues from graft-versus-host disease in mice. Blood Advances, 2017, 1, 1517-1532.	2.5	15
14	Siglec-G represses DAMP-mediated effects on T cells. JCI Insight, 2017, 2, .	2.3	37
15	Danger Signals and Graft-versus-host Disease: Current Understanding and Future Perspectives. Frontiers in Immunology, 2016, 7, 539.	2.2	85
16	SAG/Rbx2-Dependent Neddylation Regulates T-Cell Responses. American Journal of Pathology, 2016, 186, 2679-2691.	1.9	25
17	Gut microbiomeâ€“derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nature Immunology, 2016, 17, 505-513.	7.0	536
18	Host CD8Î±+Dendritic Cells May Be a Key Factor for Separating Graft-versus-Host Disease from Graft-versus-Leukemia. Biology of Blood and Marrow Transplantation, 2015, 21, 775-776.	2.0	6

#	Article	IF	Citations
19	BET bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood, 2015, 125, 2724-2728.	0.6	41
20	Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation. OncoImmunology, 2015, 4, e1016699.	2.1	8
21	Donor T Cells Intrinsic Responses to Damps Regulated By Siglec-G-CD24 Axis Mitigate Gvhd but Maintain GVL in Experimental BMT Model. Blood, 2015, 126, 229-229.	0.6	1
22	Genome-Wide Binding Studies of Acetyl-STAT3 Demonstrates a Novel Regulatory Pathway in Dendritic Cells. Blood, 2015, 126, 647-647.	0.6	0
23	The Role of Dendritic Cells in Graft-Versus-Tumor Effect. Frontiers in Immunology, 2014, 5, 66.	2.2	14
24	Siglec-Gâ€“CD24 axis controls the severity of graft-versus-host disease in mice. Blood, 2014, 123, 3512-3523.	0.6	76
25	Host-derived CD8+ dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation. Blood, 2013, 121, 4231-4241.	0.6	34
26	Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 564-569.	3.3	125
27	Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoieticâ€“derived antigen-presenting cells. Blood, 2012, 119, 3844-3853.	0.6	86
28	Ikaros-Notch axis in host hematopoietic cells regulates experimental graft-versus-host disease. Blood, 2011, 118, 192-204.	0.6	94
29	Interleukin-6 Modulates Graft-versus-Host Responses after Experimental Allogeneic Bone Marrow Transplantation. Clinical Cancer Research, 2011, 17, 77-88.	3.2	155
30	Immunization with host-type CD8Î±+ dendritic cells reduces experimental acute GVHD in an IL-10â€“dependent manner. Blood, 2010, 115, 724-735.	0.6	26
31	Mesenchymal Stem Cells for Treatment and Prevention of Graft-Versus- Host Disease After Allogeneic Hematopoietic Cell Transplantation. Current Stem Cell Research and Therapy, 2009, 4, 252-259.	0.6	46
32	GVHD pathophysiology: is acute different from chronic?. Best Practice and Research in Clinical Haematology, 2008, 21, 101-117.	0.7	71
33	Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenaseâ€“dependent DC functions and regulates experimental graft-versus-host disease in mice. Journal of Clinical Investigation, 2008, 118, 2562-73.	3.9	243